NDAINTRAVENOUSPOWDER
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Mechanism of Action
benzodiazepine. BYFAVO binds to brain benzodiazepine sites (gamma amino butyric acid type A [GABA A ] receptors), while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. BYFAVO, like other benzodiazepines, did not show clear selectivity between subtypes of…
Clinical Trials (3)
Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
Started Feb 2023
Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
Started Apr 2022
The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients
Started Sep 2021
Loss of Exclusivity
LOE Date
Jan 13, 2034
95 months away
Patent Expiry
Jan 13, 2034
Company
Acacia Pharma
UK - Cambridge